Trials / Unknown
UnknownNCT02429440
Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- University Hospital Tuebingen · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Clinical Phase I/II study to investigate the feasibility and tolerability of synthetic adjuvant peptide immunisation in combination with immune adjuvants (granulocyte macrophage colony stimulating factor; Montanide ISA-51) in patients with advanced renal cell cancer (RCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | peptide vaccine | subcutaneous |
| DRUG | Granulocyte Macrophage Colony Stimulating Factor | intradermal |
| DRUG | Montanide ISA-51 | subcutaneous |
Timeline
- Start date
- 2005-05-01
- Primary completion
- 2017-10-01
- Completion
- 2018-06-01
- First posted
- 2015-04-29
- Last updated
- 2017-08-17
Source: ClinicalTrials.gov record NCT02429440. Inclusion in this directory is not an endorsement.